Key points – Brentuximab Vedotin with Nivolumab was a well tolerated salvage regimen in patients with relapsed/refractory hodgkin lymphoma, with less than 10 percent of patients treated with systemic steroids for infusion related adverse events.
Home / Resource Library / Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma